Bayesian Sample Size Determination for Single-Particle Tracking of Pathogens in Biological Fluids by Yates, Bryan
Bayesian Sample Size Determination
for Single-Particle Tracking of
Pathogens in Biological Fluids
by
Bryan Yates
A thesis
presented to the University of Waterloo
in fulfillment of the
thesis requirement for the degree of
Master of Mathematics
in
Statistics
Waterloo, Ontario, Canada, 2018
c© Bryan Yates 2018
I hereby declare that I am the sole author of this thesis. This is a true copy of the thesis,
including any required final revisions, as accepted by my examiners.
I understand that my thesis may be made electronically available to the public.
ii
Abstract
Single-particle tracking (SPT) experiments measure 2-dimensional particle position
with a high-resolution digital camera, capturing microsecond motion. SPT has al-
lowed novel investigation of membrane dynamics, enzymology, subdiffusion processes
in proteins, and serves as a burgeoning application of statistical modelling. While par-
ticle tracking statistical methodology has shown great promise, the literature is com-
paratively scarce for methods that determine the necessary number of particles to track
to assess a relevant scientific hypothesis. This work addresses this gap by providing a
Bayesian sample size determination (SSD) algorithm. Namely, this work proceeds in
two-stages, (1) model training and (2) the SSD algorithm. A single-trajectory location-
scale model incorporating fractional Brownian motion is fit using maximum likelihood
estimation for each 2-dimensional SPT trajectory. Subsequently, a multiple-trajectory
hierarchical model is fit to capture different particle dynamics caused by fluid hetero-
geneity. A Bayesian SSD algorithm follows to evaluate scientific relevance based on
population-level mean-squared displacement. The performance of the SSD algorithm
is first studied under a simulation environment. Three simplified SSD algorithms are
presented to accelerate computation. Following this, experimental data of 3,707 flu-
orescently labelled herpes-simplex virus trajectories are studied across five separate
antibody concentrations ranging 0-1000 mg/L. A detailed analysis on the practical use
of the SSD algorithm provides insight into virus dynamics as a function of antibody
concentration.
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Chapter 1
Introduction
Nanotechnology offers revolutionary imaging methods capable of single-molecule mo-
tion measurement (Moerner, 2002). In the field of rheology, typical single-particle
tracking (SPT) experiments record the position of various pathogens and foreign bod-
ies in biological fluids over time using high-resolution cameras. SPT has allowed novel
investigation of membrane dynamics (Saxton and Jacobson, 1997), enzymology (Xie
and Lu, 1999), subdiffusion processes in proteins (Kou, 2008), and serves as a bur-
geoning application of statistical modelling (Lysy et al., 2016; Mellnik et al., 2016). An
excellent review of important statistical developments in SPT can be found in Qian and
Kou (2014).
Figure 1.1 show a simplified cartoon schematic of a typical SPT experiment captur-
ing 2-dimensional particle movement. Typically, hundreds of single-particle trajecto-
ries are recorded concurrently using a high-resolution camera. This work will focus
specifically on 2-dimensional trajectories. While 3-dimensional SPT experiments are
feasible, the complexity of working in higher dimensions and the wider availability of
2-dimensional SPT data encourage use of 2-dimensional SPT trajectories. Some exper-
imental challenges of capturing SPT trajectories will be discussed in Section 1.2 which
further support the use of 2-dimensional trajectories for statistical analysis.
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Figure 1.1: SPT procedure. Diffusion is monitored for individual particles over time.
1.1 Motivating Application
This work specifically focuses on the statistical analysis and study of virus diffusion.
A subset of the immunology discipline, virology focuses on the structure, movements
patterns, and ongoing adaptation of virus and virus-like agents. SPT has offered enor-
mous insights into virus behaviour (Brandenburg and Zhuang, 2007), including how
viral material transits across cell membranes (Babcock et al., 2004), lateral mobility of
live-cell bound viruses (Ewers et al., 2005), and real-time imaging of infection pathways
(Seisenberger et al., 2001).
Understanding virus movement is critical toward improved vaccine design (Nowak
and May, 2000; Gottlieb and Johnston, 2017). Through understanding the motion and
behaviour of viruses at the micrometer level, practitioners can develop improved meth-
ods to combat virus uptake and infiltration into the human body. One modern ap-
proach to vaccine development is to study the interaction of viruses and antibodies.
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Common antibodies found in human blood and mucus are large protein molecules
produced by the immune system to defend against pathogenic bacteria and viruses.
Antibodies bind to a unique molecule, known as antigen, located on specific sites of
pathogens. Upon binding, the deleterious effects of the pathogen are neutralized. The
mechanism of which the pathogen is effectively deactivated depends on its type and
structure, but generally an antibody bound pathogen will lose ability to begin any bi-
ological process that can cause disease or sickness. Hence, knowledge of virus motion
is vital for immunologists to determine which antibodies are effective or possess great
potential for new vaccination treatments.
The virus under study in this work is the herpes-simplex virus (HSV). The inimical
culprit of cold sores and herpes, HSV is highly contagious with over 3 billion humans
infected globally (Looker et al., 2015). Thus, there is considerable need for substantially
improved vaccine design to protect future generations. The methodology developed in
this work aims to accelerate SPT research and deployment by providing a fundamental
approach to determine the required number of particles to capture in a given SPT
experiment.
1.2 Heterogeneity and Particle Dynamics
This work examines 3,707 fluorescently labelled HSV trajectories in a mucus medium,
at five separate antibody (Ab) concentrations ranging 0-1000 mg/L. Importantly, the
0 mg/L antibody concentration does not indicate no antibody is present in the mu-
cus, but rather that no external antibody concentration has been added. Particle y-axis
trajectories in the baseline environment are displayed in Figure 1.2. This restricted
1-dimensional view of the 2-dimensional experimental data offers enormous insight
into some of the principle challenges in SPT experiments and experimental data char-
acteristics, namely high-particle density, particle motion heterogeneity, and particle
disappearance (Jaqaman et al., 2008). Each of these challenges are now discussed in
terms of the current HSV data under study.
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Figure 1.2: HSV particle diffusion 1-dimensional view of SPT trajectories for 0 mg/L
antibody concentration. There is a clear variance of behaviour among different particle
trajectories, some particle trajectories are cut short, and some have very slow movement
while others show fast diffusion.
Firstly, high particle density in SPT experiments can cause neighbouring virus-virus
interaction producing unnatural changes to virus motion. To combat this, SPT exper-
iments usually require particles to have a certain separation distance to be recorded.
This work assumes the virus particles under study are strictly interacting with the fluid
medium, hence there are no virus-virus particle interactions.
A careful examination of Figure 1.2 illuminates that some SPT trajectories are cut short.
That is, though the SPT experiment runs for 20 seconds, the data available for some
virus particles in considerably shorter. This effect is primarily caused by the limited
camera focal operating range. If particles begin in the focal range of the camera and dif-
fuse out within the experiment time, only the time spent in the operating range of the
camera is recorded. Hence, these trajectories will not have a full 20-seconds of position
data. This is problematic for highly mobile particles since they have a higher chance
to diffuse outside of the camera range than less mobile particles. Therefore, this work
will distinguish between constrained (slow-moving) and unconstrained (fast-moving)
particles. The physical mechanism that causes a virus particle to become constrained
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in motion is primarily attributed to interaction with an antibody particle. This virus-
antibody interaction hinders virus motion resulting in slow diffusion. This work will
specifically study constrained HSV trajectories since these are of great interest when
studying how the level of antibody concentration impacts virus motion. The majority
of these constrained trajectories are observed in the central band visible in Figure 1.2.
Despite studying only the constrained trajectories, there are still many HSV paths that
exit the camera frame before 20 seconds. This work gives identical treatment to HSV
paths, regardless of their length, when fitting the location-scale model of Section 2.2.
While this assumption may be limiting, the shortest constrained paths still contain over
50 observations which amply allows for accurate parameter estimation.
Heterogeneity is a pervasive phenomena of SPT experimental data. In this work, het-
erogeneity refers to the varied behaviour of virus particles under a seemingly identical
physical environment. For example, while Figure 1.2 shows many particles are clus-
tered near the zero-position throughout the 20-second experiment, these trajectories
do all behave identically. A detailed view of constrained path motion in Figure 1.3
illuminates the varied diffusion behaviour of constrained trajectories. Within these
constrained paths, some particles move more slowly (trajectory number 19), while oth-
ers exhibit faster motion (trajectory number 1). This heterogeneity of particle motion
within constrained trajectories in the same experimental environment primarily arises
due to the complex fluid that surrounds each virus particle. Varying fluid viscosity,
temperature, and density all attribute to idiosyncratic particle behaviour depending
on that particles exact location in the heterogeneous medium. Moreover, the virus
particles under study are dispersed in mucus which is a viscous colloid containing
salts, immunoglobulins, enzymes, and glycoproteins. Hence, the particular location of
a virus in the medium can result in varied motion characteristic due to the structure of
the surrounding local fluid environment.
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Figure 1.3: HSV 2-dimensional constrained trajectories under the 0 mg/L antibody
environment. There is a clear variance of diffusion behaviour across paths. A black
dot indicates the starting position of the particles at the origin.
This phenomena of heterogeneity motivates the use of a more complex multi-level
model to understand population-level dynamics present in a given experimental en-
vironment. While this work will model single-path SPT trajectories using a single
location-scale model (detailed in Section 2.2), heterogeneity will be captured by a hier-
archical model discussed in Section 2.3.
1.3 Mean-Squared Displacement and Scientific Relevance
Modern SPT experiments routinely generate hundreds to a few thousand trajectories
under a single experimental environment. A wide-spread technique to characterize the
diffusive behaviour of a single particle is through mean-squared displacement (MSD)
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analysis. The MSD of a particle’s continuous-time trajectory X(t) is defined as
MSD(t) = 〈X2(t)〉 = E
[
(X(t)− X(0))2
]
, t ≥ 0.
The behaviour of the MSD over time is commonly employed to classify a particles be-
haviour, such as Brownian motion where MSD(t) ∝ t. While Brownian motion is em-
ployed to model particle motion in many areas of physics, SPT experiments routinely
reveal non-Brownian dynamics. Small particles such as viruses undergo complex in-
teractions with their surrounding medium that results in motion known as anomalous
subdiffusion. Anomalous subdiffusion is characterized through a particles MSD,
MSD(t) ∝ tα, 0 < α < 1, tmin < t < tmax,
where α is the anomalous diffusion exponent. The anomalous diffusion exponent
effectively represents the degree of subdiffusion exhibited by a particle. Lower values
of α indicate a smaller area of space will be explored by a particle as time elapses.
A typical SPT experiment contains hundreds to a few thousand trajectories. Thus, a
population-level MSD statistic is defined as
MSD(t) = E[D · tα], t ≥ 0.
where D represents a particles diffusion coefficient. A particle’s diffusion coefficient
coincides with the rate at which a particle diffuses in a fluid. The higher the value
of a particle diffusion coefficient, the faster the particle diffuses. Further discussion
of the diffusion coefficient with respect to single-trajectory modelling will commence
in Section 2.2. This population-level MSD corresponds to the expectation taken across
numerous single-particle trajectories MSD. This distinction between single-path MSD
and multiple-path (i.e. population level) MSD becomes important to determine the
scientific relevance of an experiment.
Scientific relevance in this work is determined through analysis of the population-level
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MSD for a particular experimental environment. Namely, given some SPT experiment,
practitioners wish to assess whether or not experimental findings are scientifically rel-
evant. As a concrete example of scientific relevance, consider two SPT experiments
A and B. For simplicity, assume all factors of the two experiments are identical except
that experiment A has 0 mg/L antibody concentration and experiment B has 100 mg/L
antibody concentration. A highly valuable scientific hypothesis to evaluate is whether
the addition of 100 mg/L antibody in experiment B made a scientifically meaningful
impact on particle motion. The definition of the scientific impact may take many forms.
One definition could evaluate scientific relevance based on the mean first-passage time
of experiment A compared to that of experiment B. A particles first-passage time is
defined as the amount of time the particle will take to reach a defined distance from
its starting origin. While this scientific hypothesis would prove very useful, it is not
studied in this work due to the difficulty in modelling such a process for 2-dimensional
trajectories. Rather, this work focuses on a more amenable definition of scientific rele-
vance defined using the population-level MSD. Using the same example of experiments
A and B, scientific relevance defined as a 20% reduction in population-level MSD be-
tween the two experiments is feasibly determined by the methodology developed in
this work. This thesis employs a single-path location-scale model and a population-
level hierarchical model to address whether an experiment is scientifically relevant. A
formalized definition of scientific relevance is discussed in Chapter 3.
1.4 Thesis Contribution
In recent decades, statistics continues to have an immense impact on biological science.
Stochastic processes readily lend to the analysis of biological particles (Allen, 2010;
Cherstvy et al., 2013), and computational intensive methods such as Bayesian methods
have been applied to model numerous biological phenomena (Huelsenbeck et al., 2001;
Li and Zhang, 2010; Yau et al., 2011).
While research has predominantly focused on the stochastic dynamics of particle mo-
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tion, literature is comparatively scarce for methods that determine necessary number
of particles to track to assess a scientific hypothesis. This is a sample size determi-
nation (SSD) problem. Knowledge of the required number of experiments to run is
extremely valuable for experimentalists since SPT experiments take considerable time
and regularly require expensive resources. Moreover, accurate sample-size determina-
tion can also be important for ethical reasons depending on the scientific hypothesis
under study which further supports the importance and practical significance of this
work. This thesis offers a Bayesian SSD algorithm to specifically address the number of
samples needed in an SPT experiment to assess whether an experiment is scientifically
relevant based on its population-level MSD. Namely, the SSD algorithm presented in
this work uses preliminary 2-dimensional particle trajectories from an experimental
environment to determine the number of future samples needed to assess a whether
a given difference in population-level MSD is present compared to some reference
population-level MSD (set by the practitioner). While the population-level MSD is
used to determine scientific relevance, the framework developed herein remains ex-
tremely flexible for future research to incorporate more complex scientific relevance
criterion such as mean first-passage times.
The primary SSD algorithm presented is computationally intensive. This poses prob-
lems for practical implementation since SPT experiments are generally completed on
the order of minutes to a few hours. The speed and efficiency of SSD technique will un-
doubtedly become increasingly important as SPT technology moves toward automated
tracking. The proliferation of successful deep neural networks in image recognition
(Krizhevsky et al., 2012; Wang and Yeung, 2013) has extended reach to the real-time
particle tracking domain (Zhu et al., 2017; Newby et al., 2017). Thus, as automation of
single-particle tracking trajectories becomes common there will be need for real-time
methods to instruct acquisition programs to cease operation. Therefore, three accel-
erated SSD algorithms are explored, each making a set of simplifying assumptions.
Chapter 3 delineates the main SSD algorithm and the three accelerated approxima-
tions. The accelerated SSD algorithms execute on the order of minutes and hence offer
great potential for future use in a real-time SPT experiment.
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The remainder of this thesis consists of five chapters. First, Chapter 2 presents the
statistical modelling framework. Namely, a single-trajectory location-scale model is
explored to model single virus diffusion, followed by a multiple-trajectory hierarchi-
cal model that captures heterogeneity. Chapter 3 discusses scientific relevance and
delineates the primary SSD algorithm and the three accompanying accelerated ap-
proximations. A comprehensive simulation study follows in Chapter 4. Experimental
HSV particle diffusion data is then carefully analyzed in Chapter 5. Closing remarks
and future areas of research are discussed in Chapter 6.
10
Chapter 2
Model and Calibration
This chapter builds up to a model for particle trajectories in three steps. First, a funda-
mental model for a ubiquitous scientific property of particle trajectories is described.
Next, this fundamental model is extended to single-particle 2-dimensional trajectories
experiencing low-frequency drift noise which must be disentangled from the dynam-
ical signal. Finally, the single-particle model is extended to multiple-trajectory exper-
imental populations, which experience substantially more dynamic variability than a
single, uniform-population model would predict.
2.1 Fractional Brownian Motion and Subdiffusion
Anomalous diffusion behaviour is captured in the anomalous exponent α. With a wide-
spread presence in physics (Metzler and Klafter, 2000), anomalous diffusion is found
in a variety of biological systems such as the transport of mammalian cells (Bronstein
et al., 2009), lipid granule motion in yeast cells (Jeon et al., 2011), chaotic transport
in laminar fluid flow (Solomon et al., 1993), and membrane dynamics (Saxton and
Jacobson, 1997).
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An extension to Brownian motion that incorporates a greater range of diffusion be-
haviour is known as fractional Brownian motion (fBM). The fBM process Bα(t) has
properties:
1. Continuous-time stochastic process
2. Stationary increments: ∆Bα(t1)
D
= ∆Bα(t2), where ∆Bα(t) = Bα(t+ ∆t)− Bα(t)
3. Zero-mean Gaussian process
Importantly, fBM is the only stochastic process with properties (1)-(3) that exhibits
uniform subdiffusion,
MSD(t) ∝ tα, 0 < α < 1, ∀t > 0.
The anomalous diffusion exponent of an fBM process is found in the covariance
cov(Bα(t), Bα(s)) =
1
2
(|t|α + |s|α − |t− s|α),
where subdiffusion occurs when 0 < α < 1. From a physical perspective, α can be
seen as representing the degree of subdiffusion a particle exhibits, where a smaller α
indicates stronger subdiffusive behaviour.
2.2 Single-Trajectory Location-Scale Model
Following the methods from Lysy et al. (2016), denote X(t) = (X1(t), X2(t)) as the
2-dimensional particle position at time t ≥ 0. A commonly employed subdiffusive
location-scale model is
X(t) = µt+Ψ1/2Z(t).
In two-dimensions, µ = (µ1, µ2), Ψ =
(
σ21 ρσ1σ2
ρσ1σ2 σ
2
2
)
, and Z(t) = (Z1(t), Z2(t)) are
iid copies of the fBM model. Thus, each 2-dimensional SPT time series is mapped to a
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1× 6 parameter vector denoted as ϕ, where ϕ = (α, σ1, σ2, ρ, µ1, µ2). Furthermore, the
path-wise MSD can be calculated,
MSD(t) = tr(Ψ) · tα = (σ21 + σ22 ) · tα = D · tα,
where tr(Ψ) denotes the trace of Ψ, and the substitution D = σ21 + σ
2
2 was made to
introduce the diffusion coefficient D. Recall, a particle’s diffusion coefficient coincides
with the rate at which a particle diffuses in a fluid.
In discrete form, let X = (X0,X1, · · · ,XN) be the discretely recorded time series
of length N + 1 with sampling period ∆t, with Xi = X(t = i · ∆t). Then xN×2 =
(x1, . . . , xN) is stationary where xi = Xi − Xi−1 are the increments of the discrete-time
SPT data. The increments x then have a matrix normal distribution,
x ∼MN (∆tµ, Vα,Ψ)
where ∆tN×1 = (∆t, · · · ,∆t)T. A generalization of the multivariate normal distribu-
tion to matrix-valued random variables, the matrix-normal distribution contains two
scale matrices corresponding to the row covariance Vα, and column covariance Ψ. By
properties of the matrix-normal distribution,
x ∼MN (∆tµ, Vα,Ψ) ⇐⇒ vec(x) ∼ N (vec(∆tµ), Vα ⊗Ψ), (2.1)
where vec(x) denotes the vectorization of x, and ⊗ denotes the Kronecker product.
Here, Vα is a Toeplitz matrix calculated using the autocorrelation of fBm increments.
The profile likelihood for this multivariate regression in (2.1) is,
`pro f (α|x) = −12
(
2N + N log
(
Sα
N
)
+ 2 log |Vα|
)
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where,
Sα = (x− ∆tµˆα)V−1α (x− ∆tµˆα) , µˆα = (∆tTV−1α ∆t)−1∆tTV−1α x.
The derivation of this log-likelihood can be found in Appendix A. Thus, working with
the increments x instead of the position X is computationally motivated since working
with a Toeplitz variance matrix Vα reduces the cost of each log-likelihood evaluation
from O(N3) to O(N2) via the Durbin-Levinson algorithm (Brockwell and Davis, 2009;
Lysy et al., 2016). Hence, parameter estimation for the location-scale model results in
a 1-dimensional optimization over α, for each 2-dimensional SPT time series in this
work. Estimates for Ψ and µ can then be determined by using the invariance property
of the MLE.
A simple transformation of the parameters will aide in computations going forward,
ϕ=
(
logit
(α
2
)
, log(σ21 + σ
2
2 ), log(σ
2
1 − σ22 ), logit
(ρ+ 1
2
)
, µ1, µ2
)
.
Namely, this transformation aids in the calculation of scientific relevance since the
first two parameters of ϕ are sufficient for calculating path-wise MSD. In practice each
2-dimensional SPT trajectory can be fit to the location-scale model in parallel which
greatly accelerates computation for a large number of time series under study.
2.3 Multiple-Trajectory Hierarchical Model
Hierarchical modelling features prominently in the analysis of multi-level data pro-
cesses such as in mechanical experiments (Qian and Wu, 2008), ecology (Clark, 2005;
Royle and Dorazio, 2008; Cressie et al., 2009), nanowire growth processes (Huang,
2010), and single-particle tracking (Lysy et al., 2016).
Consider M particle trajectories X1(t), · · · ,XM(t) recorded for a given antibody con-
centration. Ideally, all trajectories would have the same location-scale subdiffusive
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parameters,
Xi(t)
iid∼ f (X(t) |ϕi).
However, this is not the case in practice. As discussed in the introductory chapter,
particles experience different dynamics due to heterogeneity of the fluid and local
environment effects. This behaviour suggests the need for a more complex multi-level
model that can take into account individual particle behaviour as well as population
level effects. The following hierarchical model captures such heterogeneity among
particle trajectories in a given experimental environment,
Xi(t) |ϕi ind∼ f (X(t) |ϕi), ϕi iid∼ N (λ,Σ),
where ϕi corresponds to the ith particles location-scale subdiffusive parameters. The
hyperparameters of this hierarchical model are θ = (λ,Σ). Moving beyond a single-
path MSD presented in Section 2.2, the population-level MSD is
MSD(t) = E[D · tα | λ,Σ] (2.2)
This population-level MSD will be used to evaluate scientific relevance in the subse-
quent chapters. The likelihood function for hyperparameters θ = (λ,Σ) is
L(θ |X) =
M
∏
i=1
p(Xi | θ) =
M
∏
i=1
∫
p(Xi |ϕi)p(ϕi | θ)dϕi
which is intractable. Exact parameter inference would typically require MCMC on
high-dimensional parameter set (θ,ϕ1, · · · ,ϕM). Therefore, the following approxima-
tion (Lysy et al., 2016) is employed,
`(ϕi |Xi) ≈ −12(ϕi − ϕˆi)
′V−1i (ϕi − ϕˆi),
where ϕˆi is MLE from the location-scale model and Vi is the corresponding Fisher
information calculated from the hessian of the matrix-normal log-likelihood evaluated
at the MLE. Hence, the following likelihood `(λ,Σ,ϕ1, · · · ,ϕM |X) is approximately
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the same as the likelihood from the following "normal-normal" model,
ϕˆi |ϕi,Vi ind∼ N (ϕi,Vi)
ϕi | λ,Σ iid∼ N (λ,Σ).
Therefore, this hierarchical model effectively pools together the location-scale model
MLE ϕˆi and the corresponding Fisher information Vi. Approximate Bayesian inference
can then be performed where the parameter prior is Matrix-Normal Inverse-Wishart
(MNIW),
(λ,Σ) ∼ mniw(Λ0,Υ0,Ω0, ν0) ⇐⇒
Σ ∼ Inv-W(Ω0, ν0)
λ |Σ ∼MN (Λ0,Υ−10 ,Σ).
The approximate posterior p(λ,Σ,ϕ1, · · · ,ϕM) can be efficiently sampled from with a
Gibbs sampler. Further details on the Gibbs sampling procedure in the context of a
normal-normal hierarchical model can be found in Appendix B.
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Chapter 3
Bayesian Sample Size Determination
Let Xi(t) denote a 2-dimensional trajectory of the ith particle under a single experi-
mental environment. The model for this data given parameter θ ∈ Θ is
Xi(t)
ind∼ p(X(t) | θ).
The goal is to determine whether the particle dynamics in the experiment is scientifi-
cally meaningful. That is, the null hypothesis of no meaningfulness is formulated as
H0 : θ ∈ S0, (3.1)
where θ and S0 are determined by the scientist. Under this framework, rejecting the
null hypothesis indicates scientific relevance. This work uses the population-level MSD
in (2.2) to evaluate scientific relevance, and θ = (λ,Σ) from the multiple-trajectory hier-
archical model covered in the preceding Chapter. Namely, we consider null hypotheses
of the form
H0 : τ(θ) ∈ S0 = [τ0,∞),
where τ(θ) = E[D · tα0 | θ] is the population-level MSD at a specific time t0 determined
by the scientist, where t0 = 2 seconds in this work. Through appropriately setting S0
practitioners can assess scientific relevance, such as a 20% reduction in population-level
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MSD. A Monte Carlo approach is used to evaluate Pr(τ(θ) ∈ S0) = Pr(H0).
Next, let Xi = (Xi(t0),Xi(t1), . . . ,Xi(tNi)) denote the discretely recorded observations
for the ith particle, where tn = n∆t. Given N two-dimensional particle trajectories
X = (X1, . . . ,XN), the posterior parameter distribution is
p(θ |X) = pi(θ)
N
∏
i=1
p(Xi | θi).
We then have the posterior distribution of no scientific meaningfulness, i.e. scientific
irrelevance, as defined by (3.1):
Pr(H0 |X) = Pr{θ ∈ S0 |X
}
=
∫
S0
p(θ |X)dθ. (3.2)
Thus, conceptually, given a particular dataset X, we can evaluate whether the exper-
iment is scientifically meaningful based on based on how far Pr(H0 |X) is from 1/2.
While the calculation of (3.2) provides a decision rule for assessing scientific relevance,
values of Pr(H0 |X) close to 12 indicate low confidence in the given decision.
The Bayesian SSD problem can be formulated as follows. Suppose that we have al-
ready obtained a set of Ntr particle trajectories from a single experiment, denoted as
our training data Xtr. We wish to determine the sample size Nts of additional sam-
ples required such that the probability p0 = Pr(H0 |Xtr,Xts) based on all the data is
sufficiently far from 12 . That is, let
q0(X) = max
{
Pr(H0 |X), 1− Pr(H0 |X)
}
.
Namely, q0(X) represents the probability of being scientifically relevant or scientifically
irrelevant. Hence, experimentalists require q0(X) be close to 1 to make a decision on
whether an experiment is scientifically meaningful. Then the SSD problem is to find
N = Nts such that
QN = Pr
{
q0(Xtr,Xts) > ε |Xtr
}
> 1− φ,
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for given ε ∈ (0.5, 1) and φ ∈ (0, 1). Thus, as N → ∞ we expect QN → 1. The following
is a general Monte Carlo algorithm for estimating QN.
Algorithm 1 Monte Carlo Approximation to QN
1: procedure getQN(Xtr, Nts, B,C, ε)
2: θ(1), . . . , θ(B) ∼ post(Xtr)
3: for b = 1 : B do
4: θ
(b)
1 , . . . , θ
(b)
C ∼ POST_UPDATE(Xtr, θ(b), Nts)
5: for c = 1 : C do
6: δ
(b)
c ← IS_RELEVANT(θ(b)c , S0)
7: end for
8: pˆ(b)0 ← 1C ∑Cc=1 δ(b)c
9: qˆ(b)0 ← max( pˆ(b)0 , 1− pˆ(b)0 )
10: end for
11: QˆN ← 1B ∑Bb=1 I[qˆ(b)0 > ε]
12: return QˆN
13: end procedure
14:
15: procedure post_update(Xtr, θ, Nts)
16: generate Xts
17: return p(θ |Xtr,Xts)
18: end procedure
19:
20: procedure is_relevant(θ, S0)
21: M← 1e5
22: ϕ1, . . . ,ϕM ∼ p(ϕ | θ)
23: for m = 1 : M do
24: ηm ← Dmtαm
25: end for
26: η¯ ← 1M ∑Mm=1 ηm
27: return I[η¯ ∈ S0]
28: end procedure
The bottleneck in Algorithm 1 is the Monte Carlo or MCMC sampling from B posterior
distributions, each of the form
p(θ |Xtr,Xts) ∝
[
∏Ntri=1 p(Xi | θ)
]
·
[
∏Ntsj=1 p(Xj | θ)
]
· pi(θ).
Due to experimental time restrictions in actual laboratory settings, three methods to
accelerate computation are explored.
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3.1 Bootstrap-Variance Approximation
Maximum likelihood estimation of the location-scale model parameters for each new
time series takes considerable time for a large number of trajectories and can be
avoided through the use of bootstrapping. Bootstrapping is an incredibly powerful
method in statistics and is considered an outstanding breakthrough in the statistical
community (Efron, 1992).
Consider Ntr location-scale MLE parameter fits ϕˆi, i ∈ {1, · · ·Ntr}, and their corre-
sponding Fisher information matrices Vi. Define Si = (ϕˆi,Vi). Then further location-
scale parameter fitting for new test particle trajectories can be eliminated by drawing
with replacement from S1, . . . , SNtr . Namely, bootstrapping Nts samples from the train-
ing data acts as acquiring Nts new experimental trajectories. Updating the posterior
with the original training samples and the bootstrap samples permits sampling from
p(θ |Xtr,Xts).
While bootstrapping circumvents location-scale model fitting in this approximation, it
does not allow one to avoid MCMC posterior training. This bootstrap-variance ap-
proximation (BV) is expected to perform well as long as Ntr is large enough that the
training samples represent the population. Hence, if a large amount of heterogeneity
is expected, it can be beneficial to increase Ntr if one uses this method to ensure the
training samples capture a large number of diverse particle behaviours.
3.2 Common-Variance Approximation
A faster but less accurate approximation is to assume a common variance approxi-
mation (CV). Recall the first two terms of the transformed location-scale parameter
vector, ϕ(1) = logit
(
α
2
)
and ϕ(2) = log(σ21 + σ
2
2 ). Then the 5-dimensional parameter set
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sufficient for MSD calculation, denoted here by Γ, is:
Γ1×5 =
(
ϕ(1),ϕ(2), log(var(ϕ(1))), log(var(ϕ(2))), logit(
cov(ϕ(1), ϕ(2))√
var(ϕ(1))var(ϕ(2))
)
)
Training on Xtr, we calculate Γˆtr by fitting the location-scale model to each trajectory,
and subsequently calculate Vˆtr = Var(Γˆtr |Xtr). The following approximation then
allows for accelerated simulation of new sufficient parameter sets Γˆts,
Γ˜ | Γˆtr, Vˆtr ∼ N (Γˆtr, (1+ NtrNts )Vˆtr),
Γˆts | Γ˜, Γˆtr, Vˆtr ind∼ N
(
NtrΓˆtr + NtsΓ˜
Ntr + Nts
,
Ntr
Ntr + Nts
Vˆtr
)
.
That is, sampling Γˆts corresponds to generating new samples of the parameter set
sufficient for MSD calculation with the same uncertainty Vˆtr, relative to sample size. We
can then use these samples Γˆts to calculate the population-level MSD at a significantly
accelerated pace.
3.3 Zero-Variance Approximation
Another simplification to consider is to assume Vi = 0, denoted as the zero-variance
approximation (ZV). While this assumption effectively removes a level of the hierarchi-
cal model, it nonetheless gives reasonable results as will be presented in the simulation
section. Furthermore, the speed of ZV is comparable to CV.
The approximation is as follows. If length Nj of each trajectory is long enough, then
ϕˆj ≈ ϕj, such that
ϕˆj
iid∼ N (λ,Σ).
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Then for the noninformative prior
pi(λ,Σ) ∝ exp
{− ν+22 · log |Σ| },
the posterior distribution given X = (Xtr,Xts) and N = Ntr + Nts is
Σ |X ∼ Inv-W(S, ν+ N − 1)
λ |Σ,X ∼ N (λˆ, 1NΣ),
where λˆ = 1N ∑
N
j=1 ϕˆj and S = ∑
N
j=1(ϕˆj − λˆ)(ϕˆj − λˆ)′. While a stronger approximation
than the CV method, simulation results to follow indicate reasonable performance.
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Chapter 4
Simulation Study
To evaluate the performance of the SSD algorithms presented in Chapter 3, it is neces-
sary to explore a controlled simulation environment. While the SSD methodology has
broad applicability in a variety of scientific domains, this work focuses on a simulation
study for the motivating SPT application.
The simulation environment is modelled from the 0 mg/L antibody concentration ex-
periment in Chapter 5, focusing solely on the constrained trajectories. Hence, a single-
training dataset is used for this Chapter. True parameter values are presented in Ta-
ble 4.1. The simulation Monte Carlo parameters were set to B = 250, C = 500, and
the interval threshold for QN was set to ε = 0.8. Excellent convergence of the Gibbs
sampler can be found in Appendix C.
Table 4.1: Simulation Environment
Variable Value Description
τ0 3.57 True Population-Level MSD
Ntr 200 Number of Training Samples
L 300 Trajectory Length
∆t 1/15 Frame Rate (Hz)
t0 2 MSD Reference Time (seconds)
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Firstly, we look at the Bayesian SSD algorithms while varying the null hypothesis of
no meaningfulness, H0 : θ ∈ S0, where S0 = [τ0,∞) with τ0 = E[D · tα0 ] evaluated
at t0 = 2 seconds. By changing S0 (i.e. changing τ0) we can explore the effect of the
null hypothesis on qˆ0(Xtr,Xts). Figure 4.1 presents the qˆ0 estimates with increasing
Nts. Each row uses a different S0 set. The closer the box plots to 1, the higher the
confidence in the decision of scientific relevance.
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Figure 4.1: Effects of S0 = [τ0,∞) on qˆ0(Xtr,Xts) as a function of increasing Nts. Note
that the true population-level MSD is close to 3.5, hence the middle box plots have
values of qˆ0 closer to 0.5 for any given Nts. Furthermore, as Nts increased from 50 to
400, the expected behaviour of increasing qˆ0 is observed. This indicates that with more
paths practitioners can gain confidence on the conclusion of whether or not the SPT
trajectories lead to a scientifically relevant conclusion.
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Two immediate conclusions can be drawn from Figure 4.1. Firstly, the scientifically
relevant region impacts the spread of the qˆ0 estimates. This asymmetry is observed in
Figure 4.1 as the top-row box plots show less spread than the bottom-row box plots.
The most compelling reason for this behaviour is that qˆ0 is being calculated using the
expected value of path-wise MSDs, which exhibit a non-symmetric and strictly positive
distribution. While the effects of this asymmetry will be overlooked in this work, it
poses an interesting area for future research on how the structure of the scientifically
relevant decision criterion impacts inference.
The second take-away from Figure 4.1 is that there still remains open areas to explore
regarding the current SSD approximations. Among the four SSD algorithms, ZV seems
to underestimate qˆ0 when τ0 is set above the true population-level MSD, while it over-
estimates qˆ0 when τ0 is set below the true population-level MSD. However, when τ0 is
near the true population-level MSD (middle row in Figure 4.1), then ZV gives relatively
similar results for qˆ0 compared to the other three SSD algorithms. This behaviour could
suggest that the assumption underlying the ZV algorithm is too strong. Hence, a fruit-
ful area of further research entails a deeper analysis of the approximation assumptions
and how inference is impacted based on the structure of the null hypothesis.
4.1 Effect of Heterogeneity
Discussed in Chapter 1, heterogeneity is pervasive in SPT experiments. The level of
heterogeneity differ for a number of factors such as different experimental conditions
(e.g. temperature, fluid viscosity, local fluid density). Thus, it is of interest to explore
the impact of varying levels of heterogeneity on the Bayesian SSD algorithms. Fig-
ure 4.2 shows qˆ0 estimates as heterogeneity is increased from 10% to 100%. Here, 100%
heterogeneity corresponds to the mean posterior variance hyperparameter, denoted in
this section as Σre f , from the reference baseline simulation hierarchical model fit (i.e.
the 0 mg/L antibody concentration environment). In Figure 4.2, each level of hetero-
geneity corresponds to a modified variance matrix, i.e. 30% heterogeneity corresponds
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to an environment with a mean posterior variance hyperparameter of 0.3 · Σre f . All
box plots correspond to Ntr = 200 training paths, and Nts = 500 test paths, where each
path is of length L = 300. B = 250 estimates were simulated at each heterogeneity
level.
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Figure 4.2: Simulated qˆ0(Xtr,Xts) as a function of increasing heterogeneity. Increased
heterogeneity naturally leads to a decreasing confidence of the null hypothesis for a
fixed sample size Nts = 500. Namely, increasing the population-level heterogeneity
at a fixed sample size causes qˆ0(Xtr,Xts) estimates to fall, suggesting you need more
paths at higher levels of heterogeneity to retain a given qˆ0 level.
4.2 Performance Evaluation
This section explores whether the reported confidence in scientific relevance indeed
correlates well with the actual magnitude of the scientific response. Through simulat-
ing Nts trajectories, the percentage of time the resulting population-level MSD actually
falls in S0 = [τ0,∞) is recorded to assess P(H0|Xtr,Xts). Figure 4.3 displays the ef-
fect of S0 on pˆ0. By using simulated data, the reflected sigmoid-shaped plots can be
used as a visual check of the performance as S0 is varied. Here, τtrue denotes the true
population-level MSD from Table 4.1. It is clear that increasing Nts pushes the pˆ0 esti-
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mates closer to 0 (τ0 < τtrue) or 1 (τ0 > τtrue) for a given S0. This is expected since a
larger number of test paths will result in higher confidence in the decision of whether
an experiment is scientifically meaningful.
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Figure 4.3: P(H0|Xtr,Xts) as S0 = [τ0,∞) is varied. The reflected-sigmoidal shape be-
comes more apparent as Nts increases. This indicates that larger Nts provides increased
evidence to make a conclusion regarding scientific relevance. As τ0 moves away from
the true population-level MSD (i.e. as τ0 moves farther from τtrue) the pˆ0 estimates
approach 0 or 1. Each box corresponds to 100 simulations.
Furthermore, Table 4.2 displays QN for varying levels of Nts for each the CV and ZV
methods for τ0 set 20% below τtrue. The threshold ε = 0.8 was chosen, but may be any
value between 0.5 and 1. However the closer ε is set to 1, the larger number of Nts
samples will be needed to reach a given decision confidence.
Table 4.2: Simulation Results for CV and ZV Methods
Nts 100 400 800 1600 3200
CV: P[qˆ0 > 0.8] 0.30 0.57 0.75 0.82 0.85
ZV: P[qˆ0 > 0.8] 0.40 0.63 0.71 0.82 0.87
Furthermore, SPT laboratory experiments routinely have time restrictions on the order
of minutes to a few hours. It is therefore crucial that an SSD algorithm be efficient for
practical implementation in real-time experiments. Table 4.3 displays the computing
27
time require to run a standard simulation to estimate qˆ0. The rapid speed of ZV and
CV are significantly smaller than that of BV or the full algorithm.
Table 4.3: Simulation Speed Comparison (Nts = 400, L = 300, B = 10)
SSD Method Run Time (min)
Full 9.7
BV 5.8
CV 0.4
ZV 0.4
Given the results in the Section 4.1, ZV and CV offer very similar qˆ0 estimates to that
of the full algorithm, and therefore should be used instead of the full algorithm in
this case since they offer approximately a 20-times speed improvement. Regarding
how to select whether to use ZV or CV, this is an open problem. Due to the stronger
assumption underlying the ZV algorithm, it is recommended to use CV if results are
similar for the two algorithms. Future research studies, including those of different
particles and mediums, may reveal one of the four presented algorithms as superior
depending on the experimental setup. Hence, experimentalists should run a simula-
tion similar to the one presented in Section 4.1 anytime they are beginning an entirely
new experiment (i.e. new scientific study). This way, the behaviour of the four SSD al-
gorithms presented in this work can be analyzed and the algorithm giving the optimal
performance in terms of speed and accuracy can be selected for moving forward in an
experimental study.
4.3 Conclusion
This simulation section has addressed a wide-variety of scenarios regarding the effec-
tiveness of the proposed Bayesian SSD algorithms. Firstly, the full SSD algorithm can be
well-approximated by simpler algorithms achieving a large reduction in computation
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time. The ZV and CV algorithms achieve about a 20-fold reduction in computation
time compared to the full SSD algorithm. This is an outstanding result and further
strengthens the adoption and use of these algorithms in practice.
The impact of increasing levels of heterogeneity on inference was also explored. Larger
heterogeneity among SPT sample paths requires an increased number of test samples
Nts to achieve the same spread in qˆ0 estimates as that of lower heterogeneity environ-
ments. Therefore, practitioners must be knowledgeable of the amount of heterogeneity
expected in an experiment, and adjust their expectations accordingly for the order of
the recommended sample size.
Furthermore, the performance assessment in this section indicates an acceptable match
between the Bayesian SSD algorithms sample size recommendations and the actual re-
sults of a practitioner acquiring the suggested number of sample paths. The reflected-
sigmoidal shape of pˆ0 as Nts increases was clearly evident and supports the proper
behaviour of the SSD algorithms. Moreover, the fact that this simulation study fo-
cused on a baseline simulation with high heterogeneity present in the SPT sample
paths illustrates that high-heterogeneity experiments may require a large number of
test samples to determine scientific relevance. This poses two experimental issues.
Firstly, thousands of paths may not be experimentally feasible if resources are sig-
nificantly constrained. Secondly, if experiments are run sequentially, acquisition of
thousands of experiments may be lengthy and thus practitioners must be careful to
keep experimental conditions consistent across the same experiment.
This simulation section has explored an approach to SPT sample size determination
problem to assess scientific relevance based on population-level MSD. Nonetheless,
the scientific relevance definition is open to adjustment. This opens up a variety of
future research avenues such as scientific relevance based on statistics other than the
population-level MSD. Some innovative frontiers with significant practical applications
include first-passage time behaviour based scientific relevance. First-passage time was
not used in this work to evaluate scientific relevance due to the difficulty in modelling
the first-passage time of 2-dimensional fractional Brownian motion, however this poses
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an open area for future research. Understanding the length of time a particle takes to
diffuse a certain prescribed length may hold novel insights experimentalists can exploit
to accelerate SPT research and advance their application under study.
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Chapter 5
Application
This section extends the previous simulation study to real SPT experimental data. An-
alyzing experimental data is critical in the development of practical algorithms since
statisticians and experimental collaborators must work together to solve real-world
complex problems. This chapter begins with a detailed analysis of constrained versus
unconstrained trajectories, followed by a MSD ratio analysis to emphasize differences
in virus behaviour across varying antibody concentrations. The chapter closes with
illustrated use of the SSD algorithm in practice.
To illustrate use of the Bayesian SSD algorithm, this section compares results across
five experimental environments. Hundreds of 2-dimensional HSV trajectories were
recorded at 15 frames per second at five different levels of antibody concentration. A
summary of the data is displayed in Table 5.1.
Table 5.1: HSV Experimental Data Profile
Ab Concentration 0 mg/L 33 mg/L 100 mg/L 333 mg/L 1000 mg/L
Total Number of Paths 775 724 737 737 734
Number of Constrained Paths 141 283 432 593 574
Number of Unconstrained Paths 634 441 305 144 160
Average Length 130 (50, 302) 178 (50, 302) 214 (50, 302) 259 (50, 302) 253 (51, 302)
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5.1 Constrained and Unconstrained Trajectories
The 3,707 trajectories under study in this work were classified as either constrained
or unconstrained based on their trajectory increment standard deviation, denoted here
by ∆x and ∆y, where x and y correspond to the 2 dimensions of movement under
study. Using the increment standard deviations for each dimensional 2-dimensional
SPT trajectory, virus trajectories were labelled as constrained if log(σ∆x) < −0.3 and
log(σ∆y) < −0.3. The threshold was chosen based on Figure 5.1 to achieve reasonable
separation between the two visible clusters. Thus there are 2023 constrained SPT paths,
and 1684 unconstrained SPT paths.
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Figure 5.1: Labelling trajectories based on increment standard deviations. Each point
is calculated from a single virus trajectory, resulting in 2023 constrained paths, and
1684 unconstrained paths. A simple cut-off for identification of constrained paths was
chosen as log(σˆ∆x) < −0.3 and log(σˆ∆y) < −0.3.
Three of the location-scale parameter estimates for every SPT trajectory (both con-
strained and unconstrained) are shown in Figure 5.2. Recall, α is the anomalous diffu-
sion exponent, D is the diffusion coefficient, and µ1 is the linear drift term in the first
32
dimension of the location-scale model. There are significant differences among vary-
ing level of antibody concentration, such as the negative shift in parameter estimates
as the antibody concentration increases. This effect is expected as higher antibody
concentration should cause more HSV viruses to become constrained in motion (recall
virus-antibody interaction hinders virus movement). However, it is important to notice
that even at 1000 mg/L antibody concentration there remain virus trajectories that are
unconstrained - seen by the 1000 mg/L histograms where there are paths that retain
large logit(α/2) and log(D). In physical terms this suggests that there are some viruses
in solution that plainly do not interact with the antibody. While outside the scope of
this work, an open area of research in virology could pose and analyze the physical
mechanism of why some virus particles do not interact with the corresponding anti-
body.
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Figure 5.2: Differences across three location-scale parameters are directly visible as the
antibody concentration increases from 0 mg/L to 1000 mg/L. A drift toward smaller
values is seen across the three parameters as the antibody concentration increases.
Extending the analysis to the joint distribution of the location-scale parameters further
illustrates the differences between constrained and unconstrained labelled trajectories.
Figure 5.3 displays joint plots for three of the parameters from the location-scale model.
Constrained and unconstrained trajectories are again colour-labelled. Unconstrained
paths clearly exhibit larger anomalous diffusion exponent, larger diffusion coefficient,
and larger linear drift. Based on the separation between the two cluster formations
34
in Figure 5.3, the simplistic method of labelling trajectories as constrained and un-
constrained reasonably partitions the location-scale model parameters. Namely, con-
strained trajectories arise as slow moving particles exhibiting low anomalous diffusion
exponent, low diffusion coefficient, and a small linear drift. An increasingly com-
plicated separation technique for labelling constrained and unconstrained trajectories
such as using a mixture-model is an open area to explore.
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Figure 5.3: Joint distribution view of three of the locaiton-scale parameters for all
trajectories across the five antibody concentrations. Upper diagonal values correspond
to the Pearson correlation between each parameter pair. Each trajectory is colour-
labelled as constrained or unconstrained.
Furthermore, analysis of MSD behaviour offers insight into the differences between
constrained and unconstrained motion. Following the location-scale model fit and sub-
sequently fitting a hierarchical model to each experimental environment, population-
level MSD values were explored for three antibody concentrations (0, 100, and 1000
mg/L). Figure 5.4 displays these MSD values over time.
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Figure 5.4: Significant differences in population-level MSD (blue line) are seen at low
and high antibody concentrations for constrained HSV trajectories (top row). Uncon-
strained trajectories do not follow the strong decreasing pattern seen in constrained
trajectories. The red lines indicate upper (97.5%) and lower (2.5%) quantiles for single-
path MSDs. Upper and lower quantiles on the population-level MSD are indicated by
the black dashed lines. The increase in interval width is expected as time increases
where particles have time to explore a larger area.
Two conclusions can be immediately drawn from Figure 5.4, (1) there is a significant
difference in MSD upon addition of antibody for constrained trajectories, and (2) there
is sizeable heterogeneity present at all concentrations. The first conclusion stems from
the downward moving line as the antibody concentration increases for constrained
trajectories. The latter conclusion follows from the significant spread of the lower and
upper intervals (red dashed lines) at all time steps.
This section has highlighted two categories of particle motion - constrained and uncon-
strained motion. While these two categories of motion must be subjectively labelled,
the analysis presented in this section offers evidence on why and how these labels are
determined. The remaining analysis in this section will focus solely on constrained
trajectories for two reasons. Firstly, constrained trajectories indicate that the antibody-
virus interaction is likely present as discussed in Section 1.2. Since a main application
of this work is for improved vaccine design, analyzing constrained trajectories allows
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one to focus on particles that have likely interacted with the added antibody solution.
Secondly, constrained trajectories exhibit clear patterns as antibody concentration in-
creases - a phenomenon that has potential to provide important biological insights.
While unconstrained trajectories are still important, they do not exhibit significant dif-
ferences as the antibody concentration increases. Thus, constrained trajectories will
remain the focus moving forward.
5.2 Posterior Analysis
One method to explore differences across antibody concentrations is through population-
level MSD ratios. Given two separate SPT experiments (e.g. low and high anti-
body concentration), one can train the posterior distribution p(λ,Σ |Xtr) and subse-
quently analyze population-level MSD ratios from experiments i and j, that is τi/τj
with τi = E[D · tα0 |X(i)tr ], where X(i)tr corresponds to the SPT data from the ith exper-
imental environment (i.e. at a specific antibody concentration). Here t0 is set to 2
seconds and i, j ∈ {1, 2, 3, 4, 5} correspond to antibody concentrations 0, 33, 100, 333,
and 1000 mg/L, respectively. Table 5.2 displays summary statistics for each cross-
comparison of the 5 antibody concentrations for constrained trajectories. The diagonal
entires are for of each individual τi after sampling from the hierarchical model pos-
terior. The off-diagonal entires correspond to simulated MSD ratios, i.e. τi/τj. The
numbers in brackets correspond to the lower (2.5%) and upper (97.5%) quantiles.
Table 5.2: MSD Ratios for Constrained Trajectories
p(τi / τj) 0 mg/L 33 mg/L 100 mg/L 333 mg/L 1000 mg/L
0 mg/L 3.85 (1.92,7.59) 3.27 (1.46,6.77) 6.27 (2.94,12.80) 9.81 (4.78,19.68) 9.14 (4.33,18.44)
33 mg/L 1.21 (0.87,1.71) 1.98 (1.28,2.97) 3.09 (2.07,4.53) 2.88 (1.91,4.28)
100 mg/L 0.62 (0.49,0.81) 1.59 (1.15,2.18) 1.48 (1.05,2.06)
333 mg/L 0.4 (0.33,0.48) 0.94 (0.70,1.24)
1000 mg/L 0.43 (0.34,0.53)
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There are large MSD ratios when comparing low and high antibody concentration ex-
periments, however comparing the two largest antibody concentration environments
(333 and 1000 mg/L) the values are centered close to 1. This indicates that increas-
ing the antibody concentration past 333 mg/L does not cause any further reduction
in population-level MSD values. This finding may have important cost savings signifi-
cance in practice since it may suggest using more than a 333 mg/L antibody concentra-
tion is unneeded since there appears to be a saturation effect beyond this concentration.
5.3 Sample Size Considerations
Briefly discussed in the introduction, the literature on the required number of particle
trajectories to acquire for a particular SPT experimental hypothesis is scarce. Often, the
number of recorded SPT trajectories are a function of the equipment cost and experi-
ment time, with thought given to establishing scientific relevance only after trajectory
data-collection. The presented SSD algorithms have addressed this gap and offer a
computationally efficient method to accept or reject scientific hypotheses based on
population-level MSD. Figure 5.5 gives a simplified schematic to illustrate the methods
discussed in this work.
Figure 5.5: First obtain Ntr 2-dimensional single-particle trajectories, calculate single-
path location-scale parameter estimates, subsequently feed this to train a multiple-path
hierarchical model, followed by execution of the Bayesian SSD algorithm. Details such
as experimental conditions and SPT data acquisition have been omitted for clarity.
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In practice, the search for a recommended sample size N can be accomplished through
a binary-search algorithm. The practitioner will input both a recommended sample
size to initialize the search in addition to a maximum allowable number of samples (e.g.
a value of which anything higher is experimentally impractical due to time or cost).
The SSD algorithm can then commence at the recommended starting value, doubling
or halving the sample size at each step until convergence or until the algorithm states
N greater than the maximum allowable sample size is needed. Through this binary-
search, finding the require sample size for the CV and ZV methods are feasible in an
SPT experimental setting due to their significantly lower computational cost compared
to the full and BV methods.
To illustrate use of the SSD procedure, the constrained trajectories for each of the five
antibody concentration environments are analyzed using the CV algorithm. Figure 5.6
displays results for testing each of the five antibody experiments for scientific relevance,
where S0 = [τ0,∞) uses τ0 = 0.8 · τre f , where τre f is the population-level MSD of the
listed reference experiment in each row. In other words, each row in Figure 5.6 sets τ0
to 20% less than the reference experiment indicated for that row. Hence, scientific rel-
evance is defined in this experimental study as at least a 20% reduction in population-
level MSD. This exploratory analysis plots pˆ0(Xtr,Xts) to emphasize whether an exper-
iment is scientifically relevant or scientifically irrelevant. In Figure 5.6, box plots close
to 0 indicate high confidence of scientific relevance, while box plots close to 1 indicate
high confidence of scientific irrelevance, i.e. scientifically meaningless.
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Figure 5.6: pˆ0(Xtr,Xts) for the CV algorithm as Nts increase for different S0. Scientific
relevance is defined here as at least a 20% reduction in population-level MSD com-
pared to the listed reference experiment population-level MSD. Box plots close to 0
indicate high confidence of scientific relevance, while box plots close to 1 indicate high
confidence of scientific irrelevance, i.e. scientifically meaningless.
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Importantly, pˆ0(Xtr,Xts) is specifically used in this exploratory analysis in Figure 5.6
as it provides information on whether an experiment is scientifically meaningful or
meaningless. Observing the first row of box plots in Figure 5.6, all experimental en-
vironments except the 0 mg/L confidently have a population-level MSD that is 20%
less than the reference population-level MSD. Results for the second row indicate that
the 100, 333, and 1000 mg/L experiments are scientifically relevant (i.e. have at least
a 20% reduction their population-level MSD compared to 33 mg/L reference experi-
ment). Moreover, the 0 mg/L box plots in the second row are all near 1 indicating that
the 0 mg/L experiment is scientifically meaningless in this case. This is expected since
scientific relevance is defined as at least a 20% decrease in population-level MSD, and
0 mg/L has a considerably higher population-level MSD compared to the 33 mg/L
reference experiment. Continuing analysis in this manner, experimentalists can make
decisions on whether or not experiments are scientifically meaningful based on how
far pˆ0(Xtr,Xts) estimates are from 1/2. Depending on the confidence the experimen-
talist requires for evaluation of scientific relevance, the number of test samples recom-
mended by the SSD algorithm will vary. Naturally, requiring a greater proportion of
pˆ0(Xtr,Xts) estimates close to 0 or 1 will result in a larger required sample size. SPT ex-
periments often deal with hundreds or a few thousand single-particle trajectories, thus
sample recommendations of this order are should be considered feasible in practice.
The analysis presented in this section offers experimentalists an actionable approach
to analyze differences across SPT experiments in terms of scientific relevance based
on population-level MSD. This analysis should prove extremely useful for application
areas of SPT such as vaccine design, where experiments must be compared against
control experiments to indicate the efficacy of a particular vaccine in hindering virus
motion.
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Chapter 6
Discussion
Sample size determination plays a key role in developing cost-effective SPT experi-
ments and accelerating vaccine design. This work has developed a two-stage mod-
elling process, followed by a Bayesian SSD algorithm for assessing scientific relevance
of an SPT experiment based on population-level MSD. A computationally intensive
SSD algorithm was first presented. Since SPT experiments occur in real-time on the
order of minutes to hours, three simplified algorithms were offered to considerably
accelerate computation while retaining very similar statistical results as the full algo-
rithm. The latter of the two simplified algorithms, CV and ZV, are recommended for
use in practice as their computations can be completed on the order of minutes.
Through a careful simulation study, effects of heterogeneity were explored in relation
to the performance of the Bayesian SSD algorithm. Higher levels of heterogeneity nat-
urally lead to higher sample sizes to achieve a given level of confidence regarding
scientific relevance. Experimentalists have the ability to adjust the level of confidence
desired in practice, a desired flexibility built-in to the presented Bayesian SSD frame-
work.
A detailed analysis of HSV 2-dimensional particle trajectories across five antibody con-
centration levels provided numerous insights, both statistical and biological. From
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location-scale parameter analysis, a distinct trend toward increasingly confined mo-
tion was seen as the antibody concentration increased. This result follows intuition as
high quantities of antibody should increase the chance a virus interacts with antibody,
where the virus motion becomes hindered.
MSD ratios were calculated for each cross-pair of the five experiment environments.
Low antibody concentrations were shown to have large differences among MSD val-
ues, while higher antibody concentrations (333 mg/L and 1000 mg/L) gave similar
population-level MSD values (MSD ratios were near 1). This suggests that there may
be a saturation point at which further increasing the antibody concentration has negli-
gible effects. This finding has potential to offer experimentalists important cost savings
as they can objectively determine the maximum concentration of antibody needed in
an experiment. Research into whether this occurs for viruses other than HSV requires
exploration.
Overall, the algorithms presented in this work offer practitioners the ability to sig-
nificantly accelerate SPT analysis. Through statistically modelling scientific relevance,
experiments can be designed to use the minimum number of resources to asses the
scientific hypothesis under study. While this work focused on scientific hypotheses
involving population-level MSD, the SSD algorithms can readily extend to incorporate
more complex scientific relevance criterions such as first-passage times.
Finally, as real-time SPT experiments continue to proliferate, the need for fast and ef-
ficient SSD algorithms will only increase. The ability to concurrently run real-time
SSD and SPT experiments offers enormous practical opportunity. A promising future
direction is to employ the SSD algorithms developed in this work in a real-time exper-
imental system, with the goal of increasing laboratory cost-efficiency and bolstering
scientific output.
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Appendices
A Derivation of Profile Likelihood
Consider the following model,
x ∼MNN×2(∆tµ, Vα,Ψ) ⇐⇒ vec(x) ∼ N2N(vec(∆tµ),Vα ⊗Ψ).
where vec(x) denotes the vectorization of x, and ⊗ denotes the Kronecker product.
Following the supplementary material of Lysy et al. (2016), the log-likelihood that
follows from this regression model is,
`(α, µ,Ψ|x) = −1
2
{
tr
[
Ψ−1(x− ∆tµ)V−1α (x− ∆tµ)
]
+ N log |Ψ|+ 2 log |Vα|
}
.
Through setting
Sα = (x− ∆tµˆα)V−1α (x− ∆tµˆα) , µˆα = (∆tTV−1α ∆t)−1∆tTV−1α x,
the likelihood `(α, µ,Ψ|x) at a fixed α is maximized at µˆ(α) = µˆα and Ψˆ(α) = 1NSα.
Upon substituting the conditional MLEs for µ and Ψ into the full likelihood function,
we arrive at the so-called profile likelihood
`pro f (α | x) = `(α, µ = µˆ(α),Ψ = Ψˆ(α) | x) = −12
(
2N + N log
(
Sα
N
)
+ 2 log |Vα|
)
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B Gibbs Sampling from a Hierarchical Model
Consider the "normal-normal" hierarchical model
yi | µi,Vi ind∼ Nq(µi,Vi), µi iid∼ Nq(x′iβ,Σ),
where the Vi and xi are known matrices and vectors of size q× q and p× 1, and µi are
unknown random effects, and βp×q and Σq×q are the model parameters under study.
Setting Y = (y1, . . . , yn), X = (x1, . . . , xn) and µ = (µ1, . . . , µn), we have
µi |Y, β,Σ ind∼ Nq
(
Bi(x′iβ− yi) + yi, (I − Bi)Vi
)
,
where Bi = Vi(Vi + Σ)−1. However, note that
`(β,Σ |Y, µ) = `(β,Σ | µ),
such that conditioned on everything else, we can consider the likelihood for β and Σ
as being equivalent to the likelihood for
µ = Xβ+ [eij]n×q, (ei1, . . . , eiq)
iid∼ Nq(0,Σ),
which is precisely the multivariable regression model. Thus, changing form to the
commonly seen regression framework Y ← µ,
Y = Xβ+ E, (ei1, . . . , eiq)
iid∼ Nq(0,Σ),
The conjugate prior for this model is β ∼ MNIWp,q(Λ,Ω,Ψ, ν), i.e.,
Σ ∼ Inv-Wq(Ψ, ν)
β |Σ ∼MNp,q
{
Λ,Ω−1,Σ
}
.
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For this choice of prior, the posterior distribution is
Σ |Y, X ∼ Inv-Wq(Ψ+ S+ C, ν+ n)
β |Σ,Y, X ∼MNp,q
{
Λˆ, (X′X+Ω)−1,Σ
}
,
where
βˆ = (X′X)−1X′Y
S = (Y− Xβˆ)′(Y− Xβˆ) = Y′(I − H)Y
Λˆ = (X′X+Ω)−1Ω(Λ− βˆ) + βˆ
= (X′X+Ω)−1(X′Y+ΩΛ)
C = βˆ′(X′X)βˆ+Λ′ΩΛ− (X′Xβˆ+ΩΛ)′(X′X+Ω)−1(X′Xβˆ+ΩΛ)
= Y′HY+Λ′ΩΛ− (X′Y+ΩΛ)′(X′X+Ω)−1(X′Y+ΩΛ)
Thus, the Gibbs Sampler alternates between conditional draws of β, Σ, and µ.
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C MCMC Convergence
Gibbs sampling is an iterative algorithm. Thus, checking convergence is necessary to
ensure the posterior samples are meaningful. Figure C.1 displays 10000 iterations for
each of the six elements of λ. While not shown here, excellent convergence is also
achieved for the variance matrix Σ components.
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Figure C.1: Each element of λ plotted throughout sampling. There appears to be no
convergence issues (not plotting burn-in), hence these posterior results are stable to
use in simulation.
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